Investment Rating - The report maintains a "Buy" rating for the company [5][3]. Core Views - The company experienced a total revenue of 698 million yuan in H1 2025, a year-on-year decrease of 4.91%, and a net profit attributable to shareholders of 114 million yuan, down 16.72% [1][5]. - The decline in revenue and gross margin is attributed to a slight decrease in outpatient and inpatient visits, pricing adjustments due to centralized procurement, and intense market competition [1][2]. - The company is expanding its professional team and has signed a construction project for a comprehensive medical facility in Hohhot, expected to be completed by October 2026 [2]. Financial Performance Summary - For H1 2025, the revenue from consumer ophthalmology services was 359 million yuan, a decrease of 4.51%, while the revenue from basic ophthalmology services was 337 million yuan, down 5.53% [1]. - The gross margin for consumer ophthalmology services decreased by 6.8 percentage points to 41.80%, while the gross margin for basic ophthalmology services increased by 0.9 percentage points to 43.70% [1]. - The company expects revenues of 1.365 billion, 1.474 billion, and 1.614 billion yuan for 2025, 2026, and 2027, respectively, with growth rates of -2.91%, 8.00%, and 9.50% [3][10]. Future Outlook - The company plans to continue expanding its network in the core regions of North China and aims to acquire and establish more hospitals and optical centers in the Yangtze River Delta region [2]. - The company has a total of 31 ophthalmology hospitals and 29 optical centers as of H1 2025 [2].
朝聚眼科（02219）：2025H1业绩点评：专注眼科医疗服务，不断扩充专业团队